definiens: shall mean, with respect to each Drug Product, out - of - pocket costs and other costs ( in thecase of personnel costs for personnel directly involved in the marketing or promotional activities, excluding sales personneland field service supervisors ) which are incurred by a party or any of its Affiliates solely in connection with marketing orpromotional activities in the Cardiac Field, including, without limitation, costs in the following categories ( in each case to theextent incurred in connection with activities in the Cardiac Field ): ( a ) costs incurred in promoting and marketing such Drug Product, including without limitation, advertising ( includingagency fees ), market research, patient - oriented promotions, meetings, pre - launch activities and expenses relating to launchof the Drug Product, and managed markets / health authority liaisons ( but excluding detailing expenses ) ; ( b ) amounts repaid or credited for bad debts ; ( c ) costs associated with post - marketing drug safety surveillance ; ( d ) medical affairs costs, and costs associated with medical / scientific liaisons ( including regional scientific directors),medical education and publications, professional symposia, advisory boards, speaker and activity programs ; ( e ) costs of Phase IV Clinical Trials in the Territory and pharmacoeconomic studies ; ( f ) the cost of samples ; ( g ) costs of materials and programs for the training of sales force and marketing management ; ( h ) costs of promotional materials, telemarketing, e - marketing, field and headquarters ’ grants, exhibits, direct mail andsample alternative programs ; ( i ) all costs associated with the maintenance of Regulatory Approvals ; ( j ) costs associated with any sales force training agreed to by NIBRI ; provided, however, that each party will train itsown sales force ( and that of its Affiliates ) at its own expense ; [ .. * * .. ] CONFIDENTIAL TREATMENT REQUESTED3 ( k ) amounts paid to a Third Party in order to obtain freedom to operate with respect to such Drug Product in theTerritory ; and ( l ) amounts paid, whether in damages or by a settlement approved by NIBRI, to a Third Party in the Territory as a resultof any allegation of infringement by any party of a Third Party patent by the manufacture, development orcommercialization of such Drug Product